ScholarIQanswers from OpenAlex & ORCID
Timothy A. Chan
ResearcherPublications, citations & collaboration network
Timothy A. Chan is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Timothy A. Chan have?
ScholarIQindexed works
Timothy A. Chan has 1,077 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Timothy A. Chan have?
ScholarIQcitation count
Timothy A. Chan has 104,669 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Timothy A. Chan?
ScholarIQh-index
Timothy A. Chan has an h-index of 130 in OpenAlex.
What is the i10-index of Timothy A. Chan?
ScholarIQi10-index
Timothy A. Chan has an i10-index of 274 in OpenAlex.
What is the ORCID of Timothy A. Chan?
ScholarIQorcid
The ORCID for Timothy A. Chan is on the source record.
What is the OpenAlex record for Timothy A. Chan?
ScholarIQopenalex
The OpenAlex for Timothy A. Chan is on the source record.
What are the most-cited papers on Timothy A. Chan?
ScholarIQmost cited works
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Naiyer A. Rizvi, Matthew D. Hellmann, Alexandra Snyder, Pia Kvistborg, Vladimir Makarov, Jonathan J. Havel, William Lee, Jianda Yuan, Phillip Wong, Teresa Ho, Martin L. Miller, Natasha Rekhtman, André L. Moreira, Fawzia K. Ibrahim, Cameron Bruggeman, Billel Gasmi, Roberta Zappasodi, Yuka Maeda, Chris Sander, Edward B. Garon, Taha Merghoub, Jedd D. Wolchok, Ton N. Schumacher, Timothy A. Chan
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert Samstein, Chung‐Han Lee, Alexander N. Shoushtari, Matthew D. Hellmann, Ronglai Shen, Yelena Y. Janjigian, David Barron, Ahmet Zehir, Emmet Jordan, Antonio Omuro, Thomas Kaley, Sviatoslav M. Kendall, Robert J. Motzer, A. Ari Hakimi, Martin H. Voss, Paul Russo, Jonathan E. Rosenberg, Gopa Iyer, Bernard H. Bochner, Dean F. Bajorin, Hikmat Al‐Ahmadie, Jamie E. Chaft, Charles M. Rudin, Gregory J. Riely, Shrujal S. Baxi, Alan L. Ho, Richard J. Wong, David G. Pfister, Jedd D. Wolchok, Christopher A. Barker, Philip H. Gutin, Cameron Brennan, Viviane Tabar, Ingo K. Mellinghoff, Lisa M. DeAngelis, Charlotte E. Ariyan, Nancy Y. Lee, William D. Tap, Mrinal M. Gounder, Sandra P. D’Angelo, Leonard B. Saltz, Zsofia K. Stadler, Howard I. Scher, José Baselga, Pedram Razavi, Christopher A. Klebanoff, Rona Yaeger, Neil H. Segal, Geoffrey Y. Ku, Ronald P. DeMatteo, Marc Ladanyi, Naiyer A. Rizvi, Michael F. Berger, Nadeem Riaz, David B. Solit, Timothy A. Chan, Luc G.T. Morris
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan, Andrew J.S. Furness, Rachel Rosenthal, Sofie Ramskov, Rikke Lyngaa, Sunil Kumar Saini, Mariam Jamal‐Hanjani, Gareth A. Wilson, Nicolai J. Birkbak, Crispin T. Hiley, Thomas B.K. Watkins, Seema Shafi, Nirupa Murugaesu, Richard Mitter, Ayse U. Akarca, Joseph Linares, Teresa Marafioti, Jake Y. Henry, Eliezer M. Van Allen, Diana Miao, Bastian Schilling, Dirk Schadendorf, Levi A. Garraway, Vladimir Makarov, Naiyer A. Rizvi, Alexandra Snyder, Matthew D. Hellmann, Taha Merghoub, Jedd D. Wolchok, Sachet A. Shukla, Catherine J. Wu, Karl S. Peggs, Timothy A. Chan, Sine Reker Hadrup, Sergio A. Quezada, Charles Swanton
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
Timothy A. Chan, Mark Yarchoan, Elizabeth M. Jaffee, Charles Swanton, Sergio A. Quezada, Albrecht Stenzinger, Solange Peters
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Diego Chowell, Luc G.T. Morris, Claud Grigg, Jeffrey K. Weber, Robert Samstein, Vladimir Makarov, Fengshen Kuo, Sviatoslav M. Kendall, David Requena, Nadeem Riaz, Benjamin D. Greenbaum, James M. Carroll, Edward B. Garon, David M. Hyman, Ahmet Zehir, David B. Solit, Michael F. Berger, Ruhong Zhou, Naiyer A. Rizvi, Timothy A. Chan